Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement
| Autor: | Malinda N. Harris, Alan R. Spitzer, Marc A. Ellsworth, Reese H. Clark, William A. Carey |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Population Gestational Age Nitric Oxide Off-label use Risk Assessment Nitric oxide chemistry.chemical_compound Intensive Care Units Neonatal Administration Inhalation Humans Infant Very Low Birth Weight Medicine Medical prescription education Respiratory Distress Syndrome Newborn education.field_of_study Respiratory distress business.industry Infant Newborn Gestational age Off-Label Use Drug Utilization United States Confidence interval Treatment Outcome chemistry Infant Extremely Low Birth Weight Pediatrics Perinatology and Child Health Gestation Female Guideline Adherence business |
| Zdroj: | Pediatrics. 135:643-648 |
| ISSN: | 1098-4275 0031-4005 |
| DOI: | 10.1542/peds.2014-3290 |
| Popis: | BACKGROUND:Inhaled nitric oxide (iNO) therapy is an off-label medication in infants METHODS:The Pediatrix Medical Group Clinical Data Warehouse was queried for the years 2009–2013 to describe first exposure iNO use among all admitted neonates stratified by gestational age.RESULTS:Between 2009 and 2013, the rate of iNO utilization in 23- to 29-week neonates increased from 5.03% to 6.19%, a relative increase of 23% (confidence interval: 8%–40%; P = .003). Of all neonates who received iNO therapy in 2013, nearly half were CONCLUSIONS:The rates of off-label iNO use in preterm infants continue to rise despite evidence revealing no clear benefit in this population. This pattern of iNO prescription is not benign and comes with economic consequences. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|